

# TEPEZZA Patient Enrollment Form Checklist

## Enrolling Patients

- Complete the Patient Enrollment Form (PEF) to prescribe your patients TEPEZZA and enroll in Amgen By Your Side
  - The PEF must be dated and signed by both the physician and the patient
  - Include a copy of the patient's insurance card (front and back)

Recommend filling out the referring physician section of the PEF

- Initiate collection of clinical documentation needed for Prior Authorization process
  - Work with your Patient Access Liaison (PAL) to review and understand your patient's payor medical policy
  - Common criteria may include a Clinical Activity Score (CAS), prior treatments for Thyroid Eye Disease (TED), and thyroid labs

## Educating Patients

- Leverage TEPEZZA patient educational materials to set patient expectations around getting started and completing full course of therapy
- Have your patients watch the **Getting Started Video** and provide them with the **In-Office Starter Kit**

## Connecting Patients with their PALs

- Set patient expectations to answer their PAL's call to be educated on the next steps, infusion process, and getting started on TEPEZZA
- Have the patient save their PAL's contact in their phone: **It is important that a patient answers the PAL's call**

**PAL Name:** .....

**Phone Number:** .....

**Find additional resources on the back.**



**Please see Important Safety Information on the next page, and accompanying Full Prescribing Information.**

## Additional Resources:



**Patient  
Enrollment  
Form**



**Clinical  
Documentation  
Guide**



**Letter of  
Medical  
Necessity**



**Payor  
Appeal**



**Getting  
Started  
Video**

### INDICATION

TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

### IMPORTANT SAFETY INFORMATION

#### WARNINGS AND PRECAUTIONS

**Infusion Reactions:** TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache, and muscular pain. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. In patients who experience an infusion reaction, consideration should be given to premedicating with an antihistamine, antipyretic, or corticosteroid and/or administering all subsequent infusions at a slower infusion rate.

**Preexisting Inflammatory Bowel Disease:** TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD). Monitor patients with IBD for flare of disease. If IBD exacerbation is suspected, consider discontinuation of TEPEZZA.

**Hyperglycemia:** Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. In clinical trials, 10% of patients (two-thirds of whom had preexisting diabetes or impaired glucose tolerance) experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with TEPEZZA. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving TEPEZZA.

**Hearing Impairment Including Hearing Loss:** TEPEZZA may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with TEPEZZA and consider the benefit-risk of treatment with patients.

#### Adverse Reactions

The most common adverse reactions (incidence  $\geq$ 5% and greater than placebo) are muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, dry skin, weight decreased, nail disorders, and menstrual disorders.

**Please see Full Prescribing Information or visit [TEPEZZAhcp.com](https://www.tepezza.com) for more information.**



**TEPEZZA**  
teprotumumab-trbw